Neoantigens are mutations found on the surface of cancer cells that are unique to each person and tumor. The Maryland site will support the work of a new Cooperative Research and Development Agreement with the National Cancer Institute to develop adoptive cell therapies targeting patient-specific tumor neoantigens. Kite has also leased a 26,000-square-foot facility in Gaithersburg, Maryland. In addition to the Netherlands facility, Kite has recently purchased a new building in Santa Monica from Astellas Pharma that will be used for cell-therapy research, development, and the expansion of clinical manufacturing capabilities. The new facility is scheduled to be fully operational in 2020. The facility will engineer and produce cell therapies, including axicabtagene ciloleucel, a chimeric antigen receptor T cell therapy that is currently under review by the European Medicines Agency and which was approved in October 2017 in the US as Yescarta for treating adult patients with relapsed or refractory large B-cell lymphoma. The 117,000-square-foot site will be used to manufacture and deliver cell therapies to people living with cancer in Europe. Kite has leased a new facility in Hoofddorp, the Netherlands to engineer cell therapies. Talk about room for ROI! Especially considering the Kite got $11.9B for only one mRNA patent and didnt even have one FDA clearance! We have two:Īnd they are both being Reactivated if Koos can beat the buyout:įirst Offical Reddit Post.Kite Pharma, Gilead Sciences’ cell-therapy subsidiary, has leased and purchased new facilities in the US and Europe to expand its cell-therapy manufacturing capabilities. I trust those who want to can find those!Īnd, yes, its true, our IP was progressed with offical collaborations from Eli Lilly along the way:Ĭurrent Regen Market cap of about $80M. There are many more Patents listed still with USPTO. The company has developed engineered cell therapies that express either a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR), depending on the type of cancer. Now put the last two links together in your mind. Kite is an industry leader in the emerging field of cell therapy, which uses a patient's own immune cells to fight cancer. This confirms the IP Regen owns with NR2F6. Kite Pharmas leading product (KTE-C19) has received breakthrough therapy and orphan drug designations from the FDA and the European Medicines Agency. Then may I suggest you research the newest patent activity list in this $RGBP 8K: Contact Email Phone Number (310) 824-9999 Kite Pharma is a privately held development stage biotechnology company engaged in the design and development of pioneering immune-based targeted therapies to treat different cancer indications. So this above Government Publication strongly confirms the significance of NR2F6. gov publication specifically on it 8 days ago: Not only every potentially reactive molecule/compounds(part of Eli Lilly Work), but Regen also patented the way to test and discover more activity with NR2F6. So What does Regen own? In a nutshell: Just about every aspect of Nuclear Cell Receptor NR2F6. Not only that but advanced IP! With INDs. With Todays undeniable focus on attaining mRNA advances by the big boys, I honestly cant find a better mRNA IP equiped company. Kite Pharma, a subsidiary of biopharma giant Gilead Sciences, announced on Friday that it has received approval from the Food and Drug Administration for a. Not trying to turn this into to anything but cliff notes. Santosh Kesari, Eli Lilly and Company, Oregon State University. The Working IP and Collaborative History of Regen is Undeniable: Dr. Thousands of Lab hours behind Regen, and Big Pharmas pay Big bucks for cutting edge advances which offer them cutting edges in lab time. As-Is! With the two INDs reactivated(or their ownership rights transfered as part of $20B) Kite’s global head of technical operations Chris McDonald tells Endpoints News that the facility has been in the works for about four years, after Kite teamed up with its parent.

That number is repeatedly been offered to me in a strictly scientific research and Intellectual value. Regen Biopharma will either raise(or has raised) enough capital to solve its clerical issues(which it is obviously in progress of) and fund carrying the mRNA therapies it has locked up to market, or Regen is bought out by Big Pharma: Truly only one of two possible scenarios. $RGBP $RBGPP Details: ✅ $19m in Debt ✅ 2 FDA Cleared IND ✅ 20+ #mRNA Patents #NR2F6 ✅ Massive Global mRNA Focus Kite Pharma Details: ⭕️ $500m in Debt ⭕️ 0 FDA Cleared IND ⭕️ 1 #mRNA Patent ⭕️ No mRNA Attention

Kite pharma